Analysts Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target at $4.80

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have been given a consensus recommendation of “Moderate Buy” by the five brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $4.80.

Several research analysts have weighed in on KPTI shares. Robert W. Baird cut their price objective on Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $3.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th. Finally, StockNews.com raised shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th.

Institutional Investors Weigh In On Karyopharm Therapeutics

Several large investors have recently added to or reduced their stakes in KPTI. Ikarian Capital LLC lifted its holdings in Karyopharm Therapeutics by 2.3% during the first quarter. Ikarian Capital LLC now owns 409,355 shares of the company’s stock valued at $618,000 after purchasing an additional 9,355 shares during the last quarter. Point72 DIFC Ltd bought a new stake in shares of Karyopharm Therapeutics in the second quarter valued at approximately $31,000. Exchange Traded Concepts LLC lifted its stake in shares of Karyopharm Therapeutics by 34.9% during the 3rd quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock valued at $182,000 after buying an additional 56,613 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Karyopharm Therapeutics in the 2nd quarter worth approximately $143,000. Finally, Acadian Asset Management LLC purchased a new position in Karyopharm Therapeutics in the 2nd quarter valued at approximately $167,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Stock Up 1.9 %

Shares of NASDAQ:KPTI opened at $0.87 on Friday. The stock has a market cap of $108.43 million, a price-to-earnings ratio of -0.69 and a beta of 0.20. The business’s 50 day moving average is $0.79 and its 200 day moving average is $0.95. Karyopharm Therapeutics has a 12-month low of $0.62 and a 12-month high of $1.95.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.09. The firm had revenue of $42.79 million for the quarter, compared to analysts’ expectations of $36.07 million. As a group, equities research analysts expect that Karyopharm Therapeutics will post -0.93 earnings per share for the current year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).